Savara is working to initiate a second Phase 3 clinical study of Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) and expects to speak with the U.S. Food and Drug Administration (FDA) regarding a confirmatory Phase 3 study in non-cystic fibrosis bronchiectasis (NCFB).
A pivotal Phase 3 study, called AVAIL, is ongoing and is evaluating AeroVanc for the treatment of MRSA in people living with cystic fibrosis. A Phase 2a clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) infection in people living with cystic fibrosis, called ENCORE, is also ongoing.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.
Google Analytics works by means of tracking code that is added to the pages of our website. Every user is registered with a unique ID, so that Google Analytics can provide us with insight into how many unique visitors there are to the site, for example, and how many users return.
With Google Analytics, we can survey how often any single user has visited the website, what pages they visited, for how long they stayed and how they interacted with the site.
